Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Real-time Estimate Tradegate
Other stock markets
 11:42:38 31/05/2024 BST 		5-day change 1st Jan Change
32.46 EUR +3.03% Intraday chart for Daiichi Sankyo Co., Ltd. +1.93% +32.14%
05-28 RevolKa Signs Master Service Agreement with Daiichi Sankyo CI
05-27 AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients DJ

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
AQ
RevolKa Signed Master Service Agreement with Daiichi Sankyo
AQ
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
BU
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
BU
Daiichi Sankyo : Announces Appointments of Directors(251.4KB
PU
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
BU
Daiichi Sankyo : Announces Determination of Matters Relating to Acquisition and Cancellation of Own Shares(213.5KB
PU
Daiichi Sankyo : FY2023 Reference Dat
PU
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours
AQ
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB
PU
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
AQ
Daiichi Sankyo : REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB
PU
Daiichi Sankyo : Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer(204.8KB
PU
Daiichi Sankyo Announces Global Management Structure and CxOs
AQ
Daiichi Sankyo : Datopotamab Deruxtecan New Drug Application Submitted in Japan for Patients with Previously Treated Advanced HR Positive, HER2 Negative Breast Cancer(190.8KB
PU
Daiichi Sankyo : Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer (200.1KB
PU
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
BU
Daiichi Sankyo : Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets(405KB
PU
Mitsubishi Tanabe Pharma Corporation - Launch of Radicava for the Treatment of ALS in Brazil First successful launch by a partner in global expansion
AQ
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock
  5. News Daiichi Sankyo Co., Ltd.
  6. Press Releases